Clinical and therapeutic implications of nestin in small cell lung cancer

• Project/Area Number: 26461193
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Nagoya City University
• Principal Investigator: Maeno Ken 名古屋市立大学, 大学院医学研究科, 講師 (10444952)
• Co-Investigator(Kenkyū-buntansha): 小栗 鉄也 名古屋市立大学, 大学院医学研究科, 准教授 (60363925) ; 小笹 裕晃 京都大学, 医学研究科, 特定助教 (80572015)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 小細胞肺癌 / ネスチン / 肺癌 / 分子標的

Outline of Final Research Achievements

Nestin is a class VI intermediate filament protein expressed in stem/progenitor cells during　the development of the central nervous system. In this study, we examined whether the expression of nestin affect malignant feature and clinical outcome in small cell lung cancer (SCLC). In nestin knock-down and overexpression cell lines, nesin expression was related to cell proliferation in vivo and resistance to anticancer drugs. In second-line chemotherapy, nestin-positive patients evaluated by immunohistochemistry of tumor specimens tended to have a lower disease control rate than negative. Furthermore, progression free survival was significantly shorter in nestin-positive patients. Our results suggest that nestin expression lead to resistance to chemotherapy and worse outcome in SCLC patients.

Research Products

• [Journal Article] Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer (2017)
  • Author(s): Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai and Young Hak Kim
  • Journal Title: Oncotarget Volume: 8 Issue: 42 Pages: 71805-71816
  • DOI: 10.18632/oncotarget.17895
  • Peer Reviewed / Open Access
• [Journal Article] Nivolumab-induced asthma in a patient with non-small-cell lung cancer (2017)
  • Author(s): Maeno K、Fukuda S、Oguri T、Niimi A
  • Journal Title: Ann Oncol. Volume: 28 Issue: 11 Pages: 2891-2891
  • DOI: 10.1093/annonc/mdx455
  • Peer Reviewed
• [Journal Article] Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients (2017)
  • Author(s): Sone K, Oguri T, Ito K, Kitamura Y, Inoue Y, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Asano T, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A
  • Journal Title: Anticancer Res. Volume: 37 Pages: 5125-5131
  • Peer Reviewed / Open Access
• [Presentation] Expression of nestin affect resistance to chemotherapy and clinical outcome in small cell lung cancer (2018)
  • Author(s): Sone K, Maeno K, Kunii E, Takakuwa O, Takeuchi A, Fukuda S, Asano T, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Oguri T, Niimi A
  • Organizer: American Association of Cancer Research Annual Meeting 2018
  • Int'l Joint Research
• [Presentation] EGFR遺伝子変異陰性あるいは不明進行期肺癌に対するエルロチニブ治療効果予測因子としての腫瘍マーカーの検討 (2017)
  • Author(s): 竹内 章, 小栗 鉄也, 曽根 一輝, 福田 悟史, 上村 剛大, 金光 禎寛, 大久保 仁嗣, 高桑 修, 竹村 昌也, 前野 健, 伊藤 穣, 中村 敦, 新実 彰男
  • Organizer: 日本呼吸器学会学術講演会